Category Archives: AZBio News

The Fundación Instituto Valenciano de Oncología Leverages HTG Technology for Breast Cancer Laboratory-Developed Test

Posted on by

 

 

 

 

 

 

TUCSON, Ariz., Sept. 20, 2022 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced that the Fundación Instituto Valenciano de Oncología, located in Valencia, Spain (IVO), with its partners, the Fundación Pública Andaluza Progreso y Salud (FPS) and the Centro de Investigación Biomédica en Red (CIBER), have developed a laboratory-developed test (LDT) (the MPD Test) for the assessment of breast cancer recurrence based on their use of the HTG EdgeSeq™ technology.Continue reading→

Dr. Roberta Diaz Brinton is the Arizona Bioscience Researcher of the Year

Posted on by

Roberta Diaz Brinton, PhD is an internationally recognized expert in the cause and treatment of Alzheimer’s disease.  Her findings have re-shaped how the field understands the disease and unlocked the potential for new and innovative therapies to prevent and treat Alzheimer’s. Dr. Brinton will be honored by Arizona’s life science and healthcare community at the AZBio Awards on September 28, 2022 at the Phoenix Convention Center. Continue reading→

C-Path Awarded FDA Grant to Establish Public-Private Partnership to Advance Treatments for Rare Neurodegenerative Diseases

Posted on by

TUCSON, Ariz., Sept. 14, 2022 — Critical Path Institute (C-Path) has announced it will serve as the convener of the Critical Path for Rare Neurodegenerative Diseases (CP-RND), a new public-private partnership (PPP) to benefit people across multiple rare neurodegenerative diseases, supported by a grant from the U.S. Food and Drug Administration (FDA). The Agency announced the PPP today in a press release.Continue reading→

Aqualung Therapeutics Receives the AZBio Fast Lane Award and Achieves Key FDA-Related Milestones

Posted on by

Aqualung Therapeutics, an immunotherapeutics biotech company with an anti-inflammatory therapeutic platform for serious unchecked inflammatory disorders, announced the achievement of two key FDA milestones for their therapeutic mAb ALT-100. First is the successful FDA IND submission for the indication of Acute Respiratory Distress Syndrome (ARDS). Second is the scheduling of an FDA Pre-IND type B meeting (September 14th) to discuss the targeted use of ALT-100 mAb in Radiation-induced Lung Injury and Fibrosis.Continue reading→